Abstract:
본 발명은 ISRK 복합생약 추출물을 포함하는 당뇨병 및 당뇨합병증 예방 및 치료를 위한 조성물에 관한 것으로서, 본 발명의 ISRK 복합생약 추출물은 혈중 포도당 농도의 급격한 상승을 억제 및 조절하고 혈중 인슐린 분비를 증진시키며, 혈당, 중성지방, 저밀도 콜레스테롤 수준을 감소시켜 혈당증(fasting hyperglycemia)을 완화시키는 혈당강하 효능과 인슐린에 대한 저항성을 감소시킴으로서 당뇨병 및 당뇨합병증 예방 및 치료를 위한 약학조성물 및 건강기능식품에 유용하게 이용될 수 있다.
Abstract:
PURPOSE: A composition containing an extract of ISRK crude drug complex for preventing and treating diabetes and diabetes complication is provided to obtain a pharmaceutical composition and a health food for preventing and treating diabetes and diabetes complication without insulin resistance. CONSTITUTION: A pharmaceutical composition for preventing and treating diabetes and diabetes complication contains 0.001-50 wt% of an extract of crude drug complex as an active ingredient. The crude drug complex includes Helianthus tuberosus, Circium japonicum, malt, Lithospermum erythrorhizon, bamboo leaves, Cortex mori radicis, Grifola umbellate, Poria cocos, corn silk, Citrus unshiu peels, Hovenia dulcis THUNB, Hovenia dulcis, Lycium chinense, Ulmus macrocarpa, jujube, Longanae Arillus, Astragalus membranaceus BUNGE, Atractylodes japonica, Cornus fruit, Glycyrrhizae radix, Angelica gigas, Paeoniae Radix, Rehmanniae radix Cnidii rhizoma, Eucommia ulmoides, and Acanthopanacis cortex. The extract is prepared using a polar solvent selected among water, C1-C4 alcohols, and a mixture thereof. [Reference numerals] (AA) 18th August; (BB) 25th August; (CC) 1st September; (DD) 8th September; (EE) 15th September; (FF) 22th September; (GG) 29th September
Abstract:
PURPOSE: A composition containing a flower bud extract of black Panax ginseng is provided to reduce the secretion of atopic dermatitis-inducing factors in cells treated with a mite extract, thereby preventing and treating atopic dermatitis. CONSTITUTION: A pharmaceutical composition for preventing and treating atopic dermatitis contains a flower bud extract of black Panax ginseng as an active ingredient. A method for preparing the flower bud extract of black Panax ginseng comprises the steps of: washing and drying flower buds of 4-7 year old Panax ginseng at 25-65°C for 12-36 hours; steaming the dried flower buds under the pressure of 0.05-0.45 MPa at 95-155°C for 3-9 hours; and drying the steamed flower buds at 40-80°C for 8-16 hours to have a moisture content of 14% or less. The extract is a crude extract (BGFE) or a butanol-soluble extract of black Panax ginseng flower buds. A health food for preventing and treating atopic dermatitis contains the extract as an active ingredient.
Abstract:
PURPOSE: A composition containing a black ginseng extract is provided to be effectively used as a composition for preventing and treating an atopic disease since the composition does not have a side effect on a body nor a toxicity and have an atopy inducer excretion reducing effect. CONSTITUTION: A pharmaceutical composition for preventing and treating an atopic disease contains a black ginseng extract as an active ingredient. The black ginseng is obtained through one cycle of the following steps of: a first step of washing Korean ginseng roots of 4 to 6 years old in an ultrasonic cleanser for 10 minutes for 3 times and drying the ginseng roots at a temperature of 35 to 45°C for 22 to 26 hours; a second step of steaming the dried Korean ginseng roots in a steamer at a temperature of 85 to 105°C for 4 to 6 hours, except a pre-heating time; a third step of drying the Korean ginseng roots at a temperature of 55 to 65°C for 10 to 14 hours; a fourth step of steaming the Korean ginseng roots at pressure of 0.1 to 0.20 MPa at a temperature of 110 to 120°C for 5 to 7 hours; and a fifth step of drying the Korean ginseng roots in a dryer for 10 to 14 hours to obtain black ginseng roots.
Abstract:
PURPOSE: A sophoricoside derivative compound of isoflavone is provided to effectively suppress MCP-1, IL-6, and IL-8 and to prevent and treat atopic dermatitis. CONSTITUTION: A flavone derivative of novel straucture is denoted by general formula I. The flavone derivative compound is derived from Sophora japonica L. A pharmaceutical composition fore preventing and treating atopic dermatitis contains the flavone derivative compound and pharmaceutically acceptable salt thereof as an active ingredient. A health food for preventing and treating atopic dermatitis contains the flavone derivative compound or pharmaceutically acceptable salt thereof as an active ingredient. The health food is manufactured in the form of powder, granule, tablet, capsule, or beverage.
Abstract:
본 발명은 흑인삼꽃봉오리 추출물을 유효성분으로 함유하는 아토피 질환의 예방 및 치료를 위한 조성물에 관한 것으로, 본 발명의 흑인삼꽃봉오리 추출물은 THP-1 세포에서의 MCP-1, IL-6, IL-8 등의 아토피 유발 인자의 분비를 감소시키는 효능을 나타내므로 아토피질환 치료에 유용한 의약품 및 건강기능식품, 또는 식품첨가물로 이용될 수 있다.
Abstract:
본 발명은 신생혈관형성 억제 용도로서의 삼칠근, 인삼, 동충하초, 산자고, 우황, 유향 및 몰약을 혼합하여 추출한 한약 조성물에 관한 것이다. 본 발명의 조성물은 기존에 이미 사용되고 있었던 의이인, 삼칠근, 인삼, 해마, 동충하초, 산자고, 우황, 진주분 및 사향을 포함하는 한약 조성물을 개량하여 제조한 것으로, 기존의 한약 조성물보다 본 발명의 한약 조성물이 신생혈관형성 억제에 탁월한 효과가 있음이 확인되었다.
Abstract:
본 발명은 염증 및 알러지성 질환의 치료용 조성물에 관한것으로서, 상세하게는 신규 구조의 쿠마린 유도체를 유효성분으로 함유하는 염증 및 알러지성 질환에 효과적인 조성물에 관한 것이다. 본 발명의 쿠마린 유도체는 베타-헥소사미니다아제(β-hexosaminidase)분비 억제 효과 및 수동 피부 아나필락시스 반응을 감소시킴을 확인함으로써, 염증 및 알러지성 질환의 예방 및 치료를 위한 약학 조성물 및 건강기능식품으로 유용하게 이용될 수 있다. 쿠마린, 베타-헥소사미니다아제, 아나필락시스, 염증, 알러지
Abstract:
본 발명은 신생혈관형성 억제 용도로서의 삼칠근, 인삼, 동충하초, 산자고, 우황, 유향 및 몰약을 혼합하여 추출한 한약 조성물에 관한 것이다. 본 발명의 조성물은 기존에 이미 사용되고 있었던 의이인, 삼칠근, 인삼, 해마, 동충하초, 산자고, 우황, 진주분 및 사향을 포함하는 한약 조성물을 개량하여 제조한 것으로, 기존의 한약 조성물보다 본 발명의 한약 조성물이 신생혈관형성 억제에 탁월한 효과가 있음이 확인되었다.
Abstract:
PURPOSE: A sophoricoside derivative compound of isoflavone is provided to effectively suppress MCP-1, IL-6, and IL-8 and to prevent and treat atopic dermatitis. CONSTITUTION: A flavone derivative of novel straucture is denoted by general formula I. The flavone derivative compound is derived from Sophora japonica L. A pharmaceutical composition fore preventing and treating atopic dermatitis contains the flavone derivative compound and pharmaceutically acceptable salt thereof as an active ingredient. A health food for preventing and treating atopic dermatitis contains the flavone derivative compound or pharmaceutically acceptable salt thereof as an active ingredient. The health food is manufactured in the form of powder, granule, tablet, capsule, or beverage.